In This Article
- At the #AHA18 Scientific Sessions, physicians and researchers from Massachusetts General Hospital's Corrigan Minehan Heart Center present their world-leading research and innovative approaches
- This article is a preview of some can't miss sessions and presentations
- Sessions highlight approaches for the prevention and treatment of cardiac disease to late-breaking science
The American Heart Association hosts its Scientific Sessions 2018 in Chicago, Illinois from November 10-12. Physicians and researchers from the Massachusetts General Hospital Corrigan Minehan Heart Center present their world-leading research, late-breaking science, and innovative approaches for preventing and treating cardiac disease.
From machine learning to metabolic disease, the topics discussed and presented at #AHA2018 foster a dialogue that contributes to the transformation of cardiovascular care in the practice setting and the improvement of heart health for patients.
Here's a list of some can't miss Mass General sessions and presentations:
Mass General researchers have discovered that heightened amygdalar activity is linked to an increased risk of atherosclerotic disease, but what other mechanisms within the brain might contribute to an elevated cardiovascular risk? Don't miss this presentation by Michael Osborne, MD, who presents preliminary research that links noise to metabolic disease in humans.
The American Heart Association's Distinguished Scientists are a prominent group of researchers and clinicians whose work has advanced our understanding of cardiovascular diseases and stroke. This year, Mass General's own Robert Levine, MD, senior cardiologist, is recognized as an AHA Distinguished Scientist.
Dr. Levine focuses on using imaging techniques to explore mechanisms of valvular heart disease in order to develop and test more specific and effective therapies. This mission encompasses diseases of excess valve motion (prolapse, obstructive systolic anterior motion) and deficient valve tissue relative to the remodeling ventricle after a heart attack.
In this session, he presents on real-world application of machine learning and big data as they relate to advanced echocardiography analytics.
Collin Stultz, MD, PhD, is an investigator in the Research Laboratory of Electronics at MIT and a cardiologist at Mass General. Dr. Stultz's team is researching signal processing and machine learning to develop computational biomarkers that identify patients at a high risk of adverse cardiovascular events.
High Throughput Profiling Techniques to Identify Pathways Unique to Exercise-induced Heart Growth and Protection
As a part of the "Can We Develop Therapies to Mimic the Benefits of Exercise?" session, Anthony Rosenzweig, MD, chief of Cardiology, presents techniques for identifying pathways specific to exercise-induced heart growth and protection.
Dr. Rosenzweig has conducted research in animal models, finding that exercise increases the generation of new cardiomyocytes.
During the "Clinical Lipidology Update" session, Pradeep Natarajan, MD, MMSc, director of Preventive Cardiology, discusses the different benefits between lifestyle modifications and statin use based on a patient's genetic cardiovascular risk.
Dr. Natarajan researches the genetic drivers of cardiovascular disease using genetic epidemiology, large-scale sequencing studies, digital health and genotype-driven human investigation.
Which sessions are you most looking forward to? Comment below.
Refer a patient to the Mass General Heart Center
Learn more about Mass General at #AHA18